1
|
Hoyos-Bachiloglu R, Chou J, Sodroski CN, Beano A, Bainter W, Angelova M, Al Idrissi E, Habazi MK, Alghamdi HA, Almanjomi F, Al Shehri M, Elsidig N, Alaa Eldin M, Knipe DM, AlZahrani M, Geha RS. A digenic human immunodeficiency characterized by IFNAR1 and IFNGR2 mutations. J Clin Invest 2017; 127:4415-4420. [PMID: 29106381 DOI: 10.1172/jci93486] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Accepted: 09/14/2017] [Indexed: 01/29/2023] Open
Abstract
Primary immunodeficiencies are often monogenic disorders characterized by vulnerability to specific infectious pathogens. Here, we performed whole-exome sequencing of a patient with disseminated Mycobacterium abscessus, Streptococcus viridians bacteremia, and cytomegalovirus (CMV) viremia and identified mutations in 2 genes that regulate distinct IFN pathways. The patient had a homozygous frameshift deletion in IFNGR2, which encodes the signal transducing chain of the IFN-γ receptor, that resulted in minimal protein expression and abolished downstream signaling. The patient also harbored a homozygous deletion in IFNAR1 (IFNAR1*557Gluext*46), which encodes the IFN-α receptor signaling subunit. The IFNAR1*557Gluext*46 resulted in replacement of the stop codon with 46 additional codons at the C-terminus. The level of IFNAR1*557Gluext*46 mutant protein expressed in patient fibroblasts was comparable to levels of WT IFNAR1 in control fibroblasts. IFN-α-induced signaling was impaired in the patient fibroblasts, as evidenced by decreased STAT1/STAT2 phosphorylation, nuclear translocation of STAT1, and expression of IFN-α-stimulated genes critical for CMV immunity. Pretreatment with IFN-α failed to suppress CMV protein expression in patient fibroblasts, whereas expression of WT IFNAR1 restored IFN-α-mediated suppression of CMV. This study identifies a human IFNAR1 mutation and describes a digenic immunodeficiency specific to type I and type II IFNs.
Collapse
Affiliation(s)
| | - Janet Chou
- Division of Immunology, Boston Children's Hospital and Department of Pediatrics, and
| | - Catherine N Sodroski
- Department of Microbiology and Immunobiology and Harvard Program in Virology, Harvard Medical School, Boston, Massachusetts, USA
| | - Abdallah Beano
- Division of Immunology, Boston Children's Hospital and Department of Pediatrics, and
| | - Wayne Bainter
- Division of Immunology, Boston Children's Hospital and Department of Pediatrics, and
| | - Magdalena Angelova
- Department of Microbiology and Immunobiology and Harvard Program in Virology, Harvard Medical School, Boston, Massachusetts, USA
| | - Eman Al Idrissi
- Department of Pediatrics, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Murad K Habazi
- Department of Pediatrics, King Fahad Medical City, Riyadh, Saudi Arabia
| | | | - Fahd Almanjomi
- Department of Pediatrics, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Mohamed Al Shehri
- Department of Pediatrics, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Nagi Elsidig
- Department of Pediatrics, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Morsi Alaa Eldin
- Department of Pediatrics, King Fahad Medical City, Riyadh, Saudi Arabia
| | - David M Knipe
- Department of Microbiology and Immunobiology and Harvard Program in Virology, Harvard Medical School, Boston, Massachusetts, USA
| | - Mofareh AlZahrani
- Department of Pediatrics, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Raif S Geha
- Division of Immunology, Boston Children's Hospital and Department of Pediatrics, and
| |
Collapse
|